Literature DB >> 25014309

Reactivation of latent HIV-1 by new semi-synthetic ingenol esters.

Diego Pandeló José1, Koen Bartholomeeusen2, Rodrigo Delvecchio da Cunha1, Celina Monteiro Abreu1, Jan Glinski3, Thais Barbizan Ferreira da Costa4, Ana Flávia Mello Bacchi Rabay4, Luiz Francisco Pianowski Filho4, Lech W Dudycz5, Udaykumar Ranga6, Boris Matija Peterlin2, Luiz Francisco Pianowski4, Amilcar Tanuri1, Renato Santana Aguiar7.   

Abstract

The ability of HIV to establish long-lived latent infection is mainly due to transcriptional silencing of viral genome in resting memory T lymphocytes. Here, we show that new semi-synthetic ingenol esters reactivate latent HIV reservoirs. Amongst the tested compounds, 3-caproyl-ingenol (ING B) was more potent in reactivating latent HIV than known activators such as SAHA, ingenol 3,20-dibenzoate, TNF-α, PMA and HMBA. ING B activated PKC isoforms followed by NF-κB nuclear translocation. As virus reactivation is dependent on intact NF-κB binding sites in the LTR promoter region ING B, we have shown that. ING B was able to reactivate virus transcription in primary HIV-infected resting cells up to 12 fold and up to 25 fold in combination with SAHA. Additionally, ING B promoted up-regulation of P-TEFb subunits CDK9/Cyclin T1. The role of ING B on promoting both transcription initiation and elongation makes this compound a strong candidate for an anti-HIV latency drug combined with suppressive HAART.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HIV; Ingenol; Latency; NF-kB; P-TEFb; PKC; Resting cells

Mesh:

Substances:

Year:  2014        PMID: 25014309      PMCID: PMC4383768          DOI: 10.1016/j.virol.2014.05.033

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  67 in total

1.  Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator.

Authors:  Philippe Roof; Maria Ricci; Pierre Genin; Monty A Montano; Max Essex; Mark A Wainberg; Anne Gatignol; John Hiscott
Journal:  Virology       Date:  2002-04-25       Impact factor: 3.616

2.  Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1.

Authors:  T Pierson; T L Hoffman; J Blankson; D Finzi; K Chadwick; J B Margolick; C Buck; J D Siliciano; R W Doms; R F Siliciano
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 3.  The development of immune-modulating compounds to disrupt HIV latency.

Authors:  Anna Lisa Remoli; Giulia Marsili; Angela Battistini; Marco Sgarbanti
Journal:  Cytokine Growth Factor Rev       Date:  2012-07-04       Impact factor: 7.638

Review 4.  Anchoring proteins for protein kinase C: a means for isozyme selectivity.

Authors:  D Mochly-Rosen; A S Gordon
Journal:  FASEB J       Date:  1998-01       Impact factor: 5.191

Review 5.  Chemistry and biological activity of secondary metabolites in Euphorbia from Iran.

Authors:  Amir Reza Jassbi
Journal:  Phytochemistry       Date:  2006-08-04       Impact factor: 4.072

6.  The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.

Authors:  Luowei Li; Suneet Shukla; Andrew Lee; Susan H Garfield; David J Maloney; Suresh V Ambudkar; Stuart H Yuspa
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

7.  ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappaB.

Authors:  X Yang; Y Chen; D Gabuzda
Journal:  J Biol Chem       Date:  1999-09-24       Impact factor: 5.157

8.  The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes.

Authors:  Lakshmanan Ganesh; Ezra Burstein; Anuradha Guha-Niyogi; Mark K Louder; John R Mascola; Leo W J Klomp; Cisca Wijmenga; Colin S Duckett; Gary J Nabel
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

9.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

10.  Unique in vitro and in vivo thrombopoietic activities of ingenol 3,20 dibenzoate, a Ca(++)-independent protein kinase C isoform agonist.

Authors:  Frederick K Racke; Maureen Baird; Rolf F Barth; Tianyao Huo; Weilian Yang; Nilendu Gupta; Michael Weldon; Heather Rutledge
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

View more
  52 in total

Review 1.  Molecular mechanisms of HIV latency.

Authors:  Daniele C Cary; Koh Fujinaga; B Matija Peterlin
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

2.  Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus.

Authors:  Laura J Martins; Pawel Bonczkowski; Adam M Spivak; Ward De Spiegelaere; Camille L Novis; Ana Beatriz DePaula-Silva; Eva Malatinkova; Wim Trypsteen; Alberto Bosque; Linos Vanderkerckhove; Vicente Planelles
Journal:  AIDS Res Hum Retroviruses       Date:  2015-07-14       Impact factor: 2.205

Review 3.  Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Authors:  Maxime J Jean; Guillaume Fiches; Tsuyoshi Hayashi; Jian Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-12       Impact factor: 2.205

4.  Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.

Authors:  M A Rochat; E Schlaepfer; R F Speck
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

5.  Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on Antiretroviral Therapy.

Authors:  Marion Pardons; Rémi Fromentin; Amélie Pagliuzza; Jean-Pierre Routy; Nicolas Chomont
Journal:  Cell Rep       Date:  2019-11-26       Impact factor: 9.423

Review 6.  Cancer therapies in HIV cure research.

Authors:  Thomas A Rasmussen; Jenny L Anderson; Fiona Wightman; Sharon R Lewin
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

Review 7.  Natural Products and HIV/AIDS.

Authors:  Daniele C Cary; B Matija Peterlin
Journal:  AIDS Res Hum Retroviruses       Date:  2018-01-10       Impact factor: 2.205

Review 8.  Cyclin-dependent kinases as therapeutic targets for HIV-1 infection.

Authors:  Andrew P Rice
Journal:  Expert Opin Ther Targets       Date:  2016-11-10       Impact factor: 6.902

9.  Proteasomal Inhibition Potentiates Latent HIV Reactivation.

Authors:  Daniele C Cary; B Matija Peterlin
Journal:  AIDS Res Hum Retroviruses       Date:  2020-08-27       Impact factor: 2.205

Review 10.  Between a shock and a hard place: challenges and developments in HIV latency reversal.

Authors:  Jennifer M Zerbato; Harrison V Purves; Sharon R Lewin; Thomas A Rasmussen
Journal:  Curr Opin Virol       Date:  2019-04-29       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.